Journal of Antimicrobial Chemotherapy

Article	Citations
ResFinder 4.0 for predictions of phenotypes from genotypes	1521
Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder	275
COVID-19 and the potential long-term impact on antimicrobial resistance	227
Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey	171
Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9	158
Systematic review of mutations associated with resistance to the new and repurposedMycobacterium tuberculosisdrugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid	121
The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community	109
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study	103
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis	96
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19	87
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial	85
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey	83
Implications of antibiotics use during the COVID-19 pandemic: present and future	82
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia	80
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study	80
EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories	79
Favipiravir, an antiviral for COVID-19?	77
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	72
An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London	71
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola viru	67
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomize	64
Large-scale assessment of antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review	60
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries	56
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials	56
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital	54

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19	53
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study	51
Lopinavir pharmacokinetics in COVID-19 patients	50
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection	44
The changing epidemiology of carbapenemase-producingKlebsiella pneumoniaein Italy: toward polyclonal evolution with emergence of high-risk lineages	43
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections	43
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect	43
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients	43
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii	42
Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it	42
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial	41
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge	41
Oxazolidinones: mechanisms of resistance and mobile genetic elements involved	40
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU	38
Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model	37
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes	37
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections	36
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid	36
Molecular mechanisms driving thein vivodevelopment of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDRPseudomonas aeruginosainfectio	35
Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics	35
Relationship of vancomycin trough levels with acute kidney injury risk: an exposure–toxicity meta-analysis	35
Linezolid-resistant (Tn6246::fexB-poxtA) Enterococcus faecium strains colonizing humans and bovines on different continents: similarity without epidemiological link	34
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019	34
Emergence of tigecycline- and eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans	34
Molecular and functional analysis of the novel cfr(D) linezolid resistance gene identified in Enterococcus faecium	33
Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile	33
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates	33
In vitrosusceptibility ofMycobacterium abscessuscomplex and feasibility of standardizing treatment regimens	32
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinicalNeisseria gonorrhoeaeisolates from 25 European countries, 2018	32
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases	32
Impact of an antimicrobial stewardship programme on reducing broad-spectrum antibiotic use and its effect on carbapenem-resistantAcinetobacter baumannii(CRAb) in hospitals in Jordan	31
Global clonal spread of mcr-3-carrying MDR ST34 Salmonella enterica serotype Typhimurium and monophasic 1,4,[5],12:i:− variants from clinical isolates	31
Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017	31
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli	30
Genomic epidemiology of Neisseria gonorrhoeae elucidating the gonococcal antimicrobial resistance and lineages/sublineages across Brazil, 2015–16	30
Clofazimine pharmacokinetics in patients with TB: dosing implications	30
Dissemination of the blaCTX-M-15 gene among Enterobacteriaceae via outer membrane vesicles	29
IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bactera	29
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa	29
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)	29
Prevalence of antimicrobial resistance genes and its association with restricted antimicrobial use in food-producing animals: a systematic review and meta-analysis	29
AMR-Intervene: a social–ecological framework to capture the diversity of actions to tackle antimicrobial resistance from a One Health perspective	29
Large diversity of linezolid-resistant isolates discovered in food-producing animals through linezolid selective monitoring in Belgium in 2019	29
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia	29
Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?	28
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis	28
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?	28
Sustained transmission of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in China	28
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies	28
Antibiotics and healthcare facility-associatedClostridioides difficileinfection: systematic review and meta-analysis 2020 update	27

Evolution of β-lactamase-mediated cefiderocol resistance	27
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19	27
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre	27
Transferable Acinetobacter baumannii plasmid pDETAB2 encodes OXA-58 and NDM-1 and represents a new class of antibiotic resistance plasmids	27
Do high MICs predict the outcome in invasive fusariosis?	27
Indications for the use of highest priority critically important antimicrobials in the veterinary sector	26
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria	26
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection	26
High percentage of the ceftriaxone-resistantNeisseria gonorrhoeaeFC428 clone among isolates from a single hospital in Hangzhou, China	26
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications	26
ESBL-producing strains isolated from imported cases of enteric fever in England and Wales reveal multiple chromosomal integrations of blaCTX-M-15 in XDR Salmonella Typhi	26
Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)	25
Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections	25
Molecular epidemiology of carbapenemase-producingEscherichia colifrom duck farms in south-east coastal China	25
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial	25
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial	25
Studies on the role of IS1216E in the formation and dissemination of poxtA-carrying plasmids in an Enterococcus faecium clade A1 isolate	25
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis	25
Prevalence and genomic analysis of ESBL-producingEscherichia coliin retail raw meats in Singapore	25
In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa	24
Detection ofmcr-9-harbouring ESBL-producingSalmonellaNewport isolated from an outbreak in a large-animal teaching hospital in the USA	24
Molecular dynamics simulations informed by membrane lipidomics reveal the structure–interaction relationship of polymyxins with the lipid A-based outer membrane of Acinetobacter baumannii	24
Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales	24
In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies	24
Antimicrobial susceptibility of Corynebacterium diphtheriae and Corynebacterium ulcerans in Germany 2011–17	24
Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interv	24
A novel in silico antimicrobial peptide DP7 combats MDR Pseudomonas aeruginosa and related biofilm infections	24
On the island of Zanzibar people in the community are frequently colonized with the same MDR Enterobacterales found in poultry and retailed chicken meat	24
In vitroactivity of the novel antifungal olorofim against dermatophytes and opportunistic moulds includingPenicilliumandTalaromycesspecies	23
Extensive antimicrobial resistance mobilization via multicopy plasmid encapsidation mediated by temperate phages	23
Towards personalized guidelines: using machine-learning algorithms to guide antimicrobial selection	23
Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring	23
Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background	23
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial	23
Vancomycin-resistant Enterococcus faecium colonizing patients on hospital admission in Germany: prevalence and molecular epidemiology	23
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review	23
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing	23
Ganciclovir therapeutic drug monitoring in transplant recipients	23
Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK	23
In vitroactivity of rifabutin against 293 contemporary carbapenem-resistantAcinetobacter baumanniiclinical isolates and characterization of rifabutin mode of action and resistance mechan	23
Emergence of a multidrug resistance efflux pump with carbapenem resistance gene blaVIM-2 in a Pseudomonas putida megaplasmid of migratory bird origin	23
Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic	22
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa	22
Characterization of Klebsiella pneumoniae complex isolates from pigs and humans in farms in Thailand: population genomic structure, antibiotic resistance and virulence genes	22
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18	22
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study	22
Preliminary view of the global distribution and spread of the tet(X) family of tigecycline resistance genes	22
Class D β-lactamases	22
Characterization of AmpC-hyperproducing Escherichia coli from humans and dairy farms collected in parallel in the same geographical region	22
Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening	22
A review of remdesivir for COVID-19 in pregnancy and lactation	21
Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study	21
One Health compartmental analysis of ESBL-producing Escherichia coli on Reunion Island reveals partitioning between humans and livestock	21
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis	21
Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study	21
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial	21
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–	21
Novel IncFII plasmid harbouring blaNDM-4 in a carbapenem-resistant Escherichia coli of pig origin, Italy	21
A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections	21
In vivopharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria	21
Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: a mini-review	21
A novel plasmid-borne tet(X6) variant co-existing with blaNDM-1 and blaOXA-58 in a chicken Acinetobacter baumannii isolate	21
Delamanid or pretomanid? A Solomonic judgement!	21
In vitroactivity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli fro	20
Characterization of novel ISAba1-bounded tet(X15)-bearing composite transposon Tn6866 in Acinetobacter variabilis	20
IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis	20
Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases	20
Changing molecular epidemiology and characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in Japan in 2019	20
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting	20
Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates	20
Inherent colistin resistance in genogroups of the Enterobacter cloacae complex: epidemiological, genetic and biochemical analysis from the BSAC Resistance Surveillance Programme	20
Characterization and outcome of invasive infections due toPaecilomyces variotii: analysis of patients from the FungiScope® registry and literature reports	20
Neisseria gonorrhoeaeSequence Typing for Antimicrobial Resistance (NG-STAR) clonal complexes are consistent with genomic phylogeny and provide simple nomenclature, rapid visualization and antim	20
Prevalence of RND efflux pump regulator variants associated with tigecycline resistance in carbapenem-resistant Acinetobacter baumannii from a worldwide survey	20
Identification of thresholds in relationships between specific antibiotic use and carbapenem-resistant Acinetobacter baumannii (CRAb) incidence rates in hospitalized patients in Jordan	20
Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and	20
Novel tigecycline resistance gene cluster tnfxB3-tmexCD3-toprJ1b in Proteus spp. and Pseudomonas aeruginosa, co-existing with tet(X6) on an SXT/R391 integrative and	20
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China	20
IS26cannot move alone	20
Epidemiology, clinical aspects, outcomes and prognostic factors associated with Trichosporon fungaemia: results of an international multicentre study carried out at 23 medical centres	19

Molecular pathways to high-level azithromycin resistance in Neisseria gonorrhoeae	19
Establishing essential metrics for antifungal stewardship in hospitals: the results of an international Delphi survey	19
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2	19
Defining the scope of the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet): a bottom-up and One Health approach	19
Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children	19
Treating COVID-19: are we missing out the window of opportunity?	19
Revealing antibiotic cross-resistance patterns in hospitalized patients through Bayesian network modelling	19
Multiplex real-time PCR assays for the prediction of cephalosporin, ciprofloxacin and azithromycin antimicrobial susceptibility of positive Neisseria gonorrhoeae nucleic acid amplification test	19
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study	19
The effect of N-acetylcysteine in a combined antibiofilm treatment against antibiotic-resistant Staphylococcus aureus	19
Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020–21	19
Carbapenemase-producing Enterobacteriaceae in transplant patients	18
EUCAST rapid antimicrobial susceptibility testing (RAST): analytical performance and impact on patient management	18
Role of new antibiotics for KPC-producingKlebsiella pneumoniae	18
Comparative phylogenomics of ESBL-, AmpC- and carbapenemase-producing Klebsiella pneumoniae originating from companion animals and humans	18
Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study	18
Spread of ESC-, carbapenem- and colistin-resistant Escherichia coli clones and plasmids within and between food workers in Lebanon	18
Rapid spread of critical priority carbapenemase-producing pathogens in companion animals: a One Health challenge for a post-pandemic world	18
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones	18
Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations	18
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?	18
De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shoc	18
Novel SCCmec type XV (7A) and two pseudo-SCCmec variants in foodborne MRSA in China	18
Occurrence of a plasmid co-carrying cfr(D) and poxtA2 linezolid resistance genes in Enterococcus faecalis and Enterococcus casseliflavus from porcine manure, Italy	18
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments	18
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa	18
COVID-19, antibiotics and One Health: a UK environmental risk assessment	18
Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro	18
Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015–19)	17
Pyocin efficacy in a murine model of Pseudomonas aeruginosa sepsis	17
Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3	17
Repositioning rafoxanide to treat Gram-negative bacilli infections	17
Mobile oxazolidinone/phenicol resistance gene optrA in chicken Clostridium perfringens	17
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation	17
Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory	17
Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark	17
Impact of duration of antibiotic therapy in central venous catheter-related bloodstream infection due to Gram-negative bacilli	17
AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant Acinetobacter baumannii clinical isolates	17
Phenotypic and genomic analysis reveals Riemerella anatipestifer as the potential reservoir of tet(X) variants	17
Invasive infections withPurpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature	17
Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients	17
Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure	17
Mechanisms of antibiotic resistance of Clostridioides difficile	16
Two high-risk clones of carbapenemase-producing Klebsiella pneumoniae that cause infections in pets and are present in the environment of a veterinary referral hospital	16
Characterization of carbapenemase-producingSerratia marcescensand whole-genome sequencing for plasmid typing in a hospital in Madrid, Spain (2016–18)	16
Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and charact	16
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation	16
Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection	16
Dalbavancin for the management of osteomyelitis: a major step forward?	16
Microevolution of acquired colistin resistance in Enterobacteriaceae from ICU patients receiving selective decontamination of the digestive tract	16
Emergence of a Neisseria gonorrhoeae clone with reduced cephalosporin susceptibility between 2014 and 2019 in Amsterdam, The Netherlands, revealed by genomic population analysis	16
Antifungal activity of nikkomycin Z against Candida auris	16
High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort s	16
Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis	16
Point prevalence survey of antibiotic use in hospitals in Latin American countries	16
Detection in livestock of the human pandemic Escherichia coli ST131 fimH30(R) clone carrying blaCTX-M-27	16
Resistance/fitness trade-off is a barrier to the evolution of MarR inactivation mutants in Escherichia coli	16
Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time	16
In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae	16
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19	16
Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain	16
Treatment efficacy for pharyngeal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials	16
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods	16
Comparative genomics of ESBL-producingEscherichia coli(ESBL-Ec) reveals a similar distribution of the 10 most prevalent ESBL-Ec clones and ESBL genes among human community faecal and extra-inte	16
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers	16
Respiratory antibacterial prescribing in primary care and the COVID-19 pandemic in England, winter season 2020–21	16
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates	16
Consumption of quinolones in the community, European Union/European Economic Area, 1997–2017	16
Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections	16
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control	16
Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria	16
The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis	15
Azithromycin in patients with COVID-19: a systematic review and meta-analysis	15
When to change treatment of acute invasive aspergillosis: an expert viewpoint	15
Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: an observational, cross-sectional study	15
A novel colistin adjuvant identified by virtual screening for ArnT inhibitors	15
Emergence and genomic characterization of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in Chengdu, China	15
Emergence of livestock-associated MRSA ST398 from bulk tank milk, China	15
AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics	15
Detecting carbapenemase-producing Enterobacterales (CPE): an evaluation of an enhanced CPE infection control and screening programme in acute care	15
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital	15
Identification of 16S rRNA mutations in Mycoplasma genitalium potentially associated with tetracycline resistance in vivo but not selected in vitro in M. genitalium and	15
Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo	15
An outbreak of multiply antibiotic-resistant ST49:ST128:KL11:OCL8Acinetobacter baumanniiisolates at a Sydney hospital	15
Optical maps of plasmids as a proxy for clonal spread of MDR bacteria: a case study of an outbreak in a rural Ethiopian hospital	14
Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveil	14
Structural and mechanistic analysis of ATPase inhibitors targeting mycobacterial DNA gyrase	14
The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections	14
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales	14
Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study	14
A genome-wide analysis of Escherichia coli responses to fosfomycin using TraDIS-Xpress reveals novel roles for phosphonate degradation and phosphate transport systems	14
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2in vitroandin vivo	14
Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK	14
Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis	14
The bla and mec families of β-lactam resistance genes in the genera Macrococcus, Mammaliicoccus and Staphylococcus: an in-depth analysis with emphasis on Macrococ	14